Histological complete response after neoadjuvant XELOX in advanced gastric carcinoma

Hepato-Gastroenterology

Volumn 60, Issue 123, 2013, Pages 638-640

  Zhao, Qun ^a   Li, Yong ^a   Tian, Yuan ^a   Chen, Yan Ning ^a   Tan, Bi Bo ^a   Zhao, Xüe Feng ^a   Jiao, Zhi Kai ^a   Zhang, Zhi Dong ^a   Chang, Sheng Li ^b  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b Zhengding People's Hospital   (China)

Author keywords

Advanced gastric carcinoma; Effect; Neoadjuvant chemotherapy

Indexed keywords

CAPECITABINE PLUS OXALIPLATIN;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE DURATION; DISEASE FREE SURVIVAL; ERUCTATION; ESOPHAGOGASTRODUODENOSCOPY; ESOPHAGOJEJUNOSTOMY; GASTRECTOMY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; ROUX Y ANASTOMOSIS; STOMACH ADENOCARCINOMA; STOMACH BIOPSY; STOMACH ULCER; TREATMENT RESPONSE;

ADENOCARCINOMA; AGED; ANASTOMOSIS, ROUX-EN-Y; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; DEOXYCYTIDINE; ENDOSCOPY, DIGESTIVE SYSTEM; ESOPHAGOSTOMY; FLUOROURACIL; GASTRECTOMY; HUMANS; LYMPH NODE EXCISION; MALE; NEOADJUVANT THERAPY; NEOPLASM STAGING; STOMACH NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84879566245     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge121131     Document Type: Article

References (14)

1. Roder JD, Böttcher K, Siewert JR, et al.: Prognostic factors in gastric carcinoma: results of the German Gastric Carcinoma Study 1992. Cancer 1993; 72:2089-2097. (Pubitemid 23280131)
2. Rougier P, Lasser P, Ducreux M, et al.: Preoperative chemotherapy of locally advanced gastric cancer. Ann Oncol 1994; 5:59-68. (Pubitemid 24094626)
3. Lowy AM, Mansfield PF, Leach SD, et al.: Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 1999; 229:303-308. (Pubitemid 30191763)
4. Ajani JA, Winter K, Okawara GS, et al.: Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol 2006; 24:3953-3958. (Pubitemid 46630744)
5. Ott K, Herrmann K, Lordick F, et al.: Early Metabolic Response Evaluation by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Allows In vivo Testing of Chemosensitivity in Gastric Cancer: Long-term Results of a Prospective Study. Clinical Cancer Research 2008; 14:2012-2018. (Pubitemid 351551110)
6. Wilke H, Preusser P, Fink U, et al.: Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol 1989; 7:1318-1326. (Pubitemid 19220135)
7. Forshaw MJ, Gossage JA, Chrystal K, et al.: Neoadjuvant chemotherapy for locally advanced carcinoma of the lower oesophagus and oesophago-gastric junction. Eur J Surg Oncol 2006; 32:1114-1118. (Pubitemid 44774383)
8. Cascinu S, Scartozzi M, Labianca R, et al.: High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, gluathione and filgrastim in patients with locally advanced unresectable gastric cancer. Br J Cancer 2004; 90:1521-1525. (Pubitemid 38648232)
9. Schuhmacher CP, Fink U, Becker K, et al.: Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxorubicin, and cisplatinum: closing results after 5 years of follow-up. Cancer 2001; 91:918-927.
10. Ross P, Nicolson M, Cunningham D, et al.: Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002; 20:1996-2004. (Pubitemid 34413593)
11. Webb A, Cunningham D, Scarffe JH, et al.: Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15:261-267. (Pubitemid 27020582)
12. Wagner AD, Grothe W, Haerting J, et al.: Chemotherapy in advanced gastric cancer: a systematic review and metaanalysis based on aggregate data. J Clin Oncol 2006; 24:2903-2909. (Pubitemid 46630593)
13. Cunningham D, Allum WH, Stenning SP, et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355:11-20.
14. Bang YJ, Kim YW, Yang HK, et al.: Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012; 379:315-321.